Cite
HARVARD Citation
Campos, J. et al. (n.d.). 1918. Impact of the SARS-CoV-2–Neutralizing Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) on the Severity and Progression of COVID-19 Symptoms in the Phase 3 TACKLE Trial. Open forum infectious diseases. p. . [Online].